FDA Lifts Pause On Kezar's Liver Drug Trial—Next Stop Lupus Study

benzinga.com/news/fda/25/07/46447668/fda-lifts-pause-on-kezars-liver-drug-trial-next-stop-lupus-study

The Division of Hepatology and Nutrition of the U.S. Food and Drug Administration lifted the partial clinical hold on Kezar Life Sciences Inc.‘s (NASDAQ:KZR) completed PORTOLA Phase 2a trial evaluating zetomipzomib in autoimmune hepatitis (AIH).
AIH is a chronic liver disease in which…

This story appeared on benzinga.com, 2025-07-16 15:54:15.
The Entire Business World on a Single Page. Free to Use →